Kabra Drugs has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shyam Kabra.
In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), Kabra Drugs has informed that the Un...
Pursuant to regulation 29 of SEBI (LODR), Regulation, 2015, Kabra Drugs has informed that the meeting of the Board of Directors of the company will be held on Friday, February 01, 2019, to consider the Un-Audited fi...
Pursuant to Regulation 30 of Listing Regulations, Kabra Drugs has informed that Madhusudan Sharma, Independent Director, has rendered her resignation from the board of the Company with effect from 21 st June, 2018 due to person...
Kabra Drugs has informed about disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE....
Kabra Drugs has informed about the proceedings of the 28th Annual General Meeting of the company.
Kabra Drugs has informed about Standalone Financial Results, Limited Review for the period ended December 31, 2016.
Kabra Drugs has informed about Standalone Financial Results for the period ended September 30, 2016 and Standalone Limited Review for the period ended September 30, 2016.
The above information is a part of...
Kabra Drugs has informed that the 27th Annual General Meeting (AGM) of the Company will be held on September 28, 2016.
Kabra Drugs has informed that a meeting of the Board of Directors of the Company will be held on February 13, 2016, to approve the Unaudited financial results of the Company for the quarter ended December 31, 2015; and to delegate Board powe...